You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Complement 5a receptor (C5aR)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Influenza, Human, Infections, Respiratory Tract Infections Trial in United States (aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on

Not yet recruiting
  • Influenza, Human
  • +4 more
  • aH5N8c on Day 1
  • +4 more
  • Cullman, Alabama
  • +8 more
May 15, 2023

Aortic Stenosis Trial in Québec, Odense (Angiotensin Receptor Blockers, Placebo)

Recruiting
  • Aortic Stenosis
  • Angiotensin Receptor Blockers
  • Placebo
  • Québec, Quebec, Canada
  • +1 more
Mar 28, 2022

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

Recruiting
  • Malignant Pleural Mesothelioma, Advanced
  • Oncolytic Adenovirus H101
  • Programmed death receptor-1 inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical Unversity Second Hospital
Sep 2, 2023

Myelopathy, Compressive, Radiculopathy, Cervical Trial in Cleveland (Bilateral Cervical Keyhole Foraminotomy, Cervical

Recruiting
  • Myelopathy, Compressive
  • +2 more
  • Bilateral Cervical Keyhole Foraminotomy
  • Cervical Decompression
  • Cleveland, Ohio
    Cleveland Clinic Foundation
Jan 4, 2023

Adverse Effect Trial (normal saline, Ondansetron 4 mg, Ondansetron 8 mg)

Not yet recruiting
  • Adverse Effect
  • normal saline
  • +2 more
  • (no location specified)
Jul 25, 2022

Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary Trial in Brescia, Genova (Letrozole tablets, carboplatin

Recruiting
  • Carcinoma, Ovarian Epithelial
  • Low Grade Serous Adenocarcinoma of Ovary
  • Letrozole tablets
  • carboplatin AUC 5 and paclitaxel 175 mg/m2
  • Brescia, BS, Italy
  • +1 more
Oct 26, 2022

Atypical Hemolytic Uremic Syndrome Trial (Iptacopan)

Not yet recruiting
  • Atypical Hemolytic Uremic Syndrome
  • (no location specified)
Jun 29, 2023

Breast Tumors Trial in Shanghai (ZN-c5)

Completed
  • Breast Neoplasms
  • Shanghai, China
    Fudan University Cancer Hospital
Aug 10, 2022

Acute Myeloid Leukemia (AML) Trial in Birmingham, San Francisco, New York (ZN-d5 ZN-c3, ZN-c3)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Birmingham, Alabama
  • +2 more
Jan 3, 2023

C677T Methylenetetrahydrofolate Reductase Mutation

Completed
  • Mutation
  • infertily evaluation
  • (no location specified)
May 16, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Prostate Cancer Trial in Ann Arbor, Detroit (ARRx, Enzalutamide)

Suspended
  • Prostate Cancer
  • Ann Arbor, Michigan
  • +1 more
Dec 17, 2021

COVID-19 Trial in Belgium (Zilucoplan®, Placebo)

Completed
  • COVID-19
  • Aalst, Belgium
  • +8 more
Jan 26, 2022

Aging Trial in Glendale

Withdrawn
  • Aging
  • (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
  • Control
  • Glendale, Arizona
    Glencroft Senior Living: Retirement Community in Arizona
Jan 30, 2023

Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia Trial (HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5%

Not yet recruiting
  • Acneiform Eruption Due to Chemical
  • +2 more
  • HT-001 2% Topical Gel
  • +3 more
  • (no location specified)
Dec 3, 2022

Real-World Evidence In Patients Treated With Palbociclib

Recruiting
  • Metastatic Breast Cancer
  • Timisoara, Timiș, Romania
  • +5 more
Dec 7, 2022

CAR T-Cell Therapy Trial in Shenzhen (HEC-016(0.5×10^6 CAR-T Cells), HEC-016(0.5×10^6.5 CAR-T Cells), HEC-016(0.5×10^7 CAR-T

Recruiting
  • CAR T-Cell Therapy
  • HEC-016(0.5×10^6 CAR-T Cells)
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Luohu Hospital
Mar 3, 2022

C3G Trial in Worldwide (Placebo, iptacopan)

Recruiting
  • C3G
  • Aurora, Colorado
  • +60 more
Nov 23, 2022

LGMD2C Trial (ATA-200)

Not yet recruiting
  • LGMD2C
  • ATA-200
  • (no location specified)
Aug 1, 2023

Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor Trial in Vancouver (177Lu-DOTATOC)

Not yet recruiting
  • Neuroendocrine Tumors
  • +6 more
  • Vancouver, British Columbia, Canada
    BC Cancer
Aug 19, 2022

Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

Not yet recruiting
  • Kidney Transplant Recipients
  • Dapagliflozin 10 MG
  • Semaglutide, 1.0 mg/mL
  • Toronto, Ontario, Canada
    Toronto General Hospital
Jul 6, 2023

Inflammatory Disease, Disease Crohn, Bowel Disease Trial in Amsterdam (Infliximab subcutaneous, Immunosuppressive Agents)

Recruiting
  • Inflammatory Disease
  • +2 more
  • Infliximab subcutaneous
  • Immunosuppressive Agents
  • Amsterdam, North Holland, Netherlands
    Amsterdam UMC AMC
Sep 27, 2023

Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab + Envafolimab + mFOLFOXIRI
  • Cetuximab + mFOLFOX6/FOLFIRI
  • (no location specified)
Jul 24, 2023

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Breast Cancer Trial in Oslo, Trondheim (Aromatase Inhibitor, Bevacizumab, Epirubicine)

Completed
  • Breast Cancer
  • Aromatase Inhibitor
  • +6 more
  • Oslo, Norway
  • +2 more
Jan 5, 2023